East Hills, NY (July 11, 2007) - - Pall Corporation (NYSE:PLL) announced the establishment of a collaborative sponsorship agreement with the Research in Immune Tolerance in Transplantation (RITT) program at the Toronto General Hospital (University Health Network) located in Toronto, Canada. The research and development, training, and education activities that are the focus of this collaboration will take place in the RITT Industrial BioDevelopment Laboratory (http://www.ibdl.ca), a state of the art facility for biotherapeutic and bioassay processing and development. The RITT program is funded jointly by the Canadian federal government (Canada Foundation for Innovation), the province of Ontario (Ontario Research Foundation), and the Toronto General Hospital.
The RITT program is headed by Dr. Gary Levy, the director of the MultiOrgan Transplant Program (MOT) at the University Health Network, and one of the world leaders in both transplantation research and clinical practice. The MOT is Canada's largest organ transplantation program and one of the largest in North America. According to Dr. Levy, "This partnership with Pall Life Sciences is a key strategic alliance for our group as it brings the capabilities of one of the world's leading bioprocess companies to our program. Our focus on bench to bedside translational medicine can only be successfully achieved by partnerships between programs such as ours and companies such as Pall."
The RITT/Pall agreement involves a state-of-the-art downstream processing laboratory fully equipped with Pall filtration and chromatography equipment and supplies. Pall will also sponsor a new postdoctoral scientist position, "the Pall Life Sciences Bioprocessing Postdoctoral Scientist;" a series of education and training workshops, and a joint research program in bioprocessing.
Pall views this sponsorship as a key partnership with one of the world's leading transplantation programs. According to Sandra Covelli, Vice President, Pall Life Sciences. "Dr. Levy is a world renowned scientist and clinician in the UHN MultiOrgan Transplant Program who leads a team of clinicians and scientists at the leading edge of transplantation research and practice. Pall is proud to work with such a distinguished team."
About Pall Corporation Pall Corporation is the global leader in the rapidly growing field of filtration, separation and purification. Pall is organized into two businesses: Life Sciences and Industrial. These businesses provide leading-edge products to meet the demanding needs of customers in biotechnology, pharmaceutical, transfusion medicine, energy, electronics, municipal and industrial water purification, aerospace, transportation and broad industrial markets. Total revenues for fiscal year 2006 were $2.0 billion. The Company headquarters is in East Hills, New York with extensive operations throughout the world. For more information visit Pall at www.pall.com.
Media Contact Marcia Katz Director of Public Relations Telephone: 516-801-9851 Fax: 516-484-3649 Email: email@example.com